Trials In Focus: The Challenges Of Running Cancer Trials In Community Setting

Research shows bringing trials to community oncology centers remains a daunting task, but Verily and OneOncology aim to help with new clinical trial management software. In other trial news, MindBio’s LSD goes into Phase II; Erasca starts tumor agnostic program; the Project to Accelerate New Treatments for Tuberculosis launched an international study investigating new combinations; and more.

• Source: Shutterstock

A partnership between Alphabet’s Verily and OneOncology aims to improve the efficiency of cancer clinical trials, through the adoption of Verily’s SignalPath clinical trial management software across the OneOncology Research Network, which the companies said would help improve systems infrastructure, streamline regulatory processes and enhance collaboration with sponsors. They also hope to expand research opportunities across community oncology centers and potentially increase participation in trials, citing research showing that there are more than 1,300 cancer drugs in the pipeline, but also that participation rates in the US among adults with cancers is only 5%.

Still, studies have shown that there are a number of barriers that get in the way of expanding clinical trials...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

 

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By 

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

More from R&D

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By 

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Ribomic Positions Itself As Latest Potential Achondroplasia Competitor

 

The company announced positive Phase II data for umedaptanib pegol and plans to move it into Phase III development in fiscal year 2026.

Peter Marks Brings Genetic Medicines Street Cred To Lilly

 

FDA’s former CBER director is joining industry as senior VP of molecule discovery and head, infectious disease at Eli Lilly.